ZNF217 and acute lymphoblastic leukemia: Moreover, we found that ZNF217 is significantly overexpressed across multiple B-ALL subtypes, including high-risk B-ALL driven by MLL-r or BCR-ABL, relative to healthy controls (Figure S1K).